The 30 most recent market catalysts affecting $AZN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 25, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca's IMFINZI-EV Combo For Muscle-Invasive Bladder Cancer Granted FDA Priority Review; PDUFA Decision Expected Q4 2026
AstraZeneca announced that its supplemental Biologics License Application (sBLA) for IMFINZI in combination with enfortumab vedotin (EV) has been granted Priority Review by the FDA…
Sep 17, 2026
Corporate Catalyst
Neutral
Impact 75
Transcript: AstraZeneca Q2 2026 Earnings Conference Call
AstraZeneca's Q2 2026 earnings call transcript reveals a 6% increase in total revenue for the first half of 2026, or 11% excluding generic impacts on Farxiga and Brilinta. This ind…
Sep 14, 2026
Corporate Catalyst
Neutral
Impact 55
CNBC Halftime Report Final Trades: AstraZeneca, Leidos Holdings, Expeditors International of Washington, U.S. 10 Year Treasury
The headline primarily serves as a signal for individual stock interest, driven by recommendations from a popular financial show. While not a fundamental market driver, such mentio…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 75
Why Is AstraZeneca Stock Trading Higher Today?
AstraZeneca's latest clinical updates present a nuanced picture for investors. The eight-year follow-up data for Tagrisso in early-stage lung cancer, showing a significant reductio…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 85
Reported Earlier, AstraZeneca Says Tagrisso Reduces Risk Of Death By 48% Versus Placebo In Overall Stage IB-IIIA Trial Population, With 79% Alive At Eight Years Versus 64%
AstraZeneca reported groundbreaking Phase III trial results for its drug Tagrisso, demonstrating a 48% reduction in the risk of death compared to placebo in patients with Stage IB-…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Earlier, AstraZeneca And Daiichi Sankyo's Enhertu Cuts Risk Of Disease Progression Or Death By 37.0% Versus Pembrolizumab Plus Chemotherapy In Phase III Trial
AstraZeneca and Daiichi Sankyo announced highly positive Phase III trial results for their HER2-directed therapy, Enhertu. The drug demonstrated a 37% reduction in the risk of dise…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
Astrazeneca Secures FDA Approval for New Breast Cancer Treatment
AstraZeneca announced a trifecta of positive news: accelerated FDA approval for Etcamah in breast cancer, strong Phase 3 data for a lung cancer combination therapy (with Amgen's Im…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
AstraZeneca Says Phase 3 DeLLphi-305 Interim Analysis Showed IMFINZI Plus Amgen's Tarlatamab Met Primary Endpoint With Statistically Significant Overall Survival Improvement vs. IMFINZI Alone In Extensive-Stage Small Cell Lung Cancer
This headline represents a significant positive catalyst for both AstraZeneca and Amgen. The successful interim analysis of the DeLLphi-305 trial, showing statistically significant…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca Announces Tozorakimab Demonstrates Reduction In Participants With Chronic Obstructive Pulmonary Disease In Phase III OBERON, TITANIA Studies
AstraZeneca reported positive Phase III results for Tozorakimab in COPD, showing a statistically significant reduction in exacerbations. This is a crucial development as it validat…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca Announces Completion Of Exclusive License Agreement With Dizal Pharmaceutical For Worldwide Rights To ZEGFROVY For $600M Upfront, Up To $900M In Milestones, Plus Tiered Royalties; US Launch Planned Q4 2026
This headline represents a significant corporate catalyst within the pharmaceutical sector. AstraZeneca's acquisition of ZEGFROVY, a potential blockbuster in lung cancer, strengthe…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca, Amgen Score Phase 3 Win in Debilitating Swallowing Disease
AstraZeneca and Amgen reported strong Phase 3 results for Tezspire in treating Eosinophilic Esophagitis (EoE), a debilitating swallowing disease. This is significant because it ope…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial
AstraZeneca and Amgen reported positive high-level results from the Phase III CROSSING trial for TEZSPIRE in eosinophilic esophagitis (EoE). The drug met both co-primary and all ke…
Aug 17, 2026
Corporate Catalyst
Bearish
Impact 65
AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies
AstraZeneca reported a mixed bag of clinical trial results for its lung cancer treatments. The SAFFRON Phase 3 study for Tagrisso and Orpathys, and the DESTINY-Lung04 Phase 3 trial…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 85
AstraZeneca And Daiichi Sankyo Report DESTINY‑Lung04 Phase III Trial Results; ENHERTU Improves Progression‑Free Survival Versus Standard Of Care In HER2‑Mutant NSCLC
AstraZeneca and Daiichi Sankyo reported positive high-level results from their DESTINY-Lung04 Phase III trial for ENHERTU, demonstrating a statistically significant and clinically …
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca And HUTCHMED’s Savolitinib, In Combination With TAGRISSO, Delivers Significant Survival Benefits In SAFFRON Phase III EGFRm Lung Cancer Trial
AstraZeneca and HUTCHMED reported positive Phase III SAFFRON trial results for their savolitinib and TAGRISSO combination in EGFRm NSCLC patients with MET overexpression/amplificat…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca shares are trading higher after reports suggesting that the company didn't have any merger discussions with Bristol Myers Squibb.
The headline suggests that the market is reacting positively to the absence of merger discussions between AstraZeneca and Bristol Myers Squibb. This removes a significant overhang …
Aug 3, 2026
Corporate Catalyst
Neutral
Impact 75
Jim Cramer Senses a 'Fake Out' in Rumored AstraZeneca, Bristol Myers Squibb $400 Billion Mega-Merger
This filing discusses Jim Cramer's skepticism about a potential $400 billion mega-merger between AstraZeneca and Bristol Myers Squibb, despite reports from the Financial Times. The…
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 65
AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
The filing details pre-market declines for several prominent stocks, each with specific drivers. AstraZeneca's reported merger talks with Bristol Myers Squibb, while potentially tr…
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 95
AstraZeneca shares are trading lower following reports suggesting the company is in discussions with Bristol Myers Squibb to merge.
A potential merger between AstraZeneca and Bristol Myers Squibb would be a major corporate catalyst, reshaping the pharmaceutical landscape. For AstraZeneca, the 'lower trading' su…
Aug 2, 2026
Corporate Catalyst
Neutral
Impact 95
AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger
This filing discloses that AstraZeneca and Bristol Myers Squibb are reportedly in talks for a massive $400 billion merger. This is a significant corporate catalyst as it would crea…
Jul 28, 2026
Market Technicals
Bearish
Impact 55
Dow Gains Over 250 Points Amid Lower Oil Prices: Investor Sentiment Weakens, Greed Index Remains In ‘Fear’ Zone
The filing indicates a day of mixed signals for the market. While the Dow saw a notable gain, attributed to declining oil prices and potential U.S.-Iran deal talks, the broader mar…
Jul 27, 2026
Market Technicals
Bullish
Impact 65
Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earnings
The filing indicates a positive start to the trading day for US markets, with major indices showing gains. AstraZeneca's strong Q2 earnings, particularly the EPS beat, served as a …
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 75
Pipeline Speed Bump Doesn't Shake AstraZeneca's $80 Billion Revenue Ambition
AstraZeneca's Q2 2026 results presented a mixed picture, with an earnings beat but a revenue miss. More significantly, the company disclosed disappointing Phase 3 trial results for…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 85
AstraZeneca Announces That Results From Its CLARITY-Gastric01 Global Phase III Trial Showed That Sonesitatug Vedotin Demonstrated Statistically Significant And Highly Clinically Meaningful Improvement In Overall Survival
AstraZeneca's Sonesitatug Vedotin (Sone-Ve) achieved its dual primary endpoint of overall survival (OS) in 3rd and later-line treatment for advanced Claudin 18.2-positive gastric c…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca Reconfirms FY2026 Guidance, Expecting Mid-To-High Single-Digit Revenue Growth And Low Double-Digit Core EPS Growth At Constant Exchange Rates
AstraZeneca's reconfirmation of its 2026 guidance, particularly the mid-to-high single-digit revenue growth and low double-digit core EPS growth at constant exchange rates, indicat…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 92
AstraZeneca Q2 Adj. EPS $2.63 Beats $2.48 Estimate, Sales $15.384B Miss $15.459B Estimate
AstraZeneca's Q2 earnings report presents a nuanced picture. The significant beat in adjusted EPS, coupled with a substantial year-over-year increase, is a positive indicator of pr…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca's Etcamah Receives EU Approval To Treat Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast
AstraZeneca announced the EU approval of Etcamah for a specific type of breast cancer. This is a significant positive development for the company as it opens up a new, large market…
Jul 14, 2026
Corporate Catalyst
Bearish
Impact 75
AstraZeneca shares are trading lower after the company announced it entered into an exclusive global license agreement with Dizal, where it will pay $600 million upfront and up to $900 million in milestones and royalties.
This headline represents a significant corporate catalyst for AstraZeneca, as the $600 million upfront payment is a substantial capital outlay, potentially impacting short-term ear…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 75
AstraZeneca Announced Earlier It Entered Exclusive Global License Agreement With Dizal For Novel Oral EGFR Inhibitor Zegfrovy For Lung Cancer; AstraZeneca To Pay $600M Upfront, Up To $900M In Milestones, Plus Royalties
This headline represents a significant corporate catalyst within the pharmaceutical sector. AstraZeneca's acquisition of exclusive global rights to Zegfrovy, a novel EGFR inhibitor…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.